ArticleMovement disorders clinical practice2025
Multimodality Brain Imaging Markers in Progressive Supranuclear Palsy Subtypes and Parkinson's Disease.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Advanced Eye Movement Features Measured by Quantitative Oculography as Candidate Biomarkers for Progressive Supranuclear Palsy.Diagnostics (Basel, Switzerland) · 2026Review
- Subregional thalamic atrophy in Progressive Supranuclear Palsy: A machine learning study.NeuroImage. Clinical · 2026Article
- Spectrum of Dystonia in Progressive Supranuclear Palsy: A Prospective Observational Study and Review of Literature.Tremor and other hyperkinetic movements (New York, N.Y.) · 2026Observational
- A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome.International journal of molecular sciences · 2025Review
- The combination of theScientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe new classification of progressive supranuclear palsy (PSP) subtypes necessitates identifying radiological biomarkers to support the clinical diagnosis.
objectiveThe goal was to test if magnetic resonance imaging (MRI) morphometry, diffusion tensor imaging (DTI), susceptibility-weighted imaging (SWI), or [18F]fluorodeoxyglucose (
methodsMidbrain/pons (M/P) area ratio, middle/superior cerebellar peduncle (MCP/SCP) width ratio, magnetic resonance parkinsonism indices (MRPI and MRPI2) and midbrain antero-posterior (AP) diameter were measured. Region of interest-based DTI, SWI, and
resultsFour PSP subtypes (n = 85) and 24 PD were studied. MRI morphometry and DTI could differentiate PSP-Richardson syndrome (PSP-RS) from PSP-parkinsonism, PSP-postural instability, and PD (area under curve >0.7). SWI did not differentiate among PSP subtypes or PD.
conclusionsMRI morphometry and DTI differentiated PSP-RS from the other common PSP subtypes and PD and may be tested as a radiological marker of PSP-RS in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.